MML Investors Services LLC raised its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,308 shares of the pharmaceutical company’s stock after buying an additional 1,815 shares during the period. MML Investors Services LLC’s holdings in GlaxoSmithKline were worth $4,935,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Renaissance Technologies LLC boosted its position in GlaxoSmithKline by 6.9% during the second quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock valued at $610,776,000 after buying an additional 989,181 shares during the period. Equity Investment Corp boosted its position in GlaxoSmithKline by 3.9% during the first quarter. Equity Investment Corp now owns 2,776,791 shares of the pharmaceutical company’s stock valued at $116,042,000 after buying an additional 105,044 shares during the period. Parametric Portfolio Associates LLC boosted its position in GlaxoSmithKline by 4.1% during the first quarter. Parametric Portfolio Associates LLC now owns 2,765,250 shares of the pharmaceutical company’s stock valued at $115,560,000 after buying an additional 107,713 shares during the period. Brandes Investment Partners LP boosted its position in GlaxoSmithKline by 2.1% during the first quarter. Brandes Investment Partners LP now owns 2,085,398 shares of the pharmaceutical company’s stock valued at $87,149,000 after buying an additional 42,656 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in GlaxoSmithKline by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock valued at $67,626,000 after buying an additional 88,148 shares during the period. Institutional investors and hedge funds own 11.16% of the company’s stock.
In related news, Director Plc Glaxosmithkline purchased 177,777 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $45.00 per share, with a total value of $7,999,965.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.
Shares of GlaxoSmithKline stock traded down $0.14 during trading on Friday, reaching $40.89. 76,720 shares of the stock were exchanged, compared to its average volume of 2,031,593. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The stock’s fifty day moving average is $41.15 and its 200 day moving average is $40.58. The firm has a market cap of $102.21 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 1.96 and a beta of 0.70. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $42.49.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. Equities analysts forecast that GlaxoSmithKline plc will post 2.96 earnings per share for the current year.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Backdoor Roth IRA
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.